William Fairey - Oct 31, 2023 Form 3 Insider Report for AILERON THERAPEUTICS INC (ALRN)

Role
Director
Signature
/s/ Manuel C. Alves-Aivado, M.D., Ph.D., as attorney-in-fact for William Fairey
Stock symbol
ALRN
Transactions as of
Oct 31, 2023
Transactions value $
$0
Form type
3
Date filed
11/2/2023, 08:50 PM
Previous filing
Jun 14, 2023
Next filing
Apr 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALRN Stock Option (right to buy) Oct 31, 2023 Common Stock 17.1K $4.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 31, 2023, the Issuer completed its merger with Lung Therapeutics, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated October 31, 2023. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 100,000 shares of Lung Therapeutics, Inc. common stock originally granted on November 17, 2021, which option was converted into an option to purchase 17,064 shares of Issuer common stock. The shares underlying the option vest annually on each anniversary of the grant date until the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on each applicable vesting date.

Remarks:

Exhibit 24.1 Power of Attorney